Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
investigational drug |
| gptkbp:canBe |
treatment of inflammatory diseases
|
| gptkbp:CASNumber |
1622921-15-6
|
| gptkbp:developedBy |
gptkb:Walter_and_Eliza_Hall_Institute_of_Medical_Research
|
| gptkbp:hasBiologicalActivity |
immunotherapy
|
| gptkbp:hasMolecularFormula |
C20H17N5O2S
|
| https://www.w3.org/2000/01/rdf-schema#label |
WEHI-345
|
| gptkbp:inhibitedBy |
gptkb:RIPK2
|
| gptkbp:IUPACName |
N-(5-(4-phenoxyphenyl)-1,3,4-oxadiazol-2-yl)benzamide
|
| gptkbp:PubChem_CID |
71587753
|
| gptkbp:bfsParent |
gptkb:RIPK2
|
| gptkbp:bfsLayer |
8
|